ati-5923 and Renal-Insufficiency--Chronic

Chronic kidney disease (CKD) complicates warfarin anticoagulation partially through its effect on CYP2C9 activity. Tecarfarin, a novel vitamin K antagonist, is not metabolized by CYP2C9. To evaluate the effect of CKD on their metabolism, we measured PK parameters of warfarin and tecarfarin in subjects with and without CKD. CKD subjects with estimated glomerular filtration rate < 30 mL/min not on dialysis (

Topics: Adult; Aged; Anticoagulants; Area Under Curve; Benzoates; Blood Coagulation; Coumarins; Cross-Over Studies; Cytochrome P-450 CYP2C9; Drug Interactions; Drug Monitoring; Female; Glomerular Filtration Rate; Half-Life; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Patient Safety; Pharmacogenomic Variants; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States; Warfarin; Young Adult